Dipeptidyl peptidase-4 (DPP-4) inactivates both incretin hormones (GIP, GLP-1), therefore DPP-4 inhibitors are used in the treatment of type 2 diabetes.[5] The prevalence of fatty liver disease in a population based study was 34% over 90% of which was due to non-alcoholic causes (NAFLD) that is generally asymptomatic, frequently associated with obesity, type 2 diabetes and metabolic syndrome.[6], [7]. Here, DPP4 is linked to obesity due to melanocortin 4 receptor deficiency.